Inclisiran-Silencing the Cholesterol, Speaking Up the Prognosis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Jul 2

PMID 34199468

Citations 8

Authors

Sylwester Rogula

Ewelina Blazejowska

Aleksandra Gasecka

Lukasz Szarpak

Milosz J Jaguszewski

Tomasz Mazurek

Krzysztof J Filipiak

Affiliations

Soon will be listed here.

Abstract

The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in cardiovascular risk reduction due to its well-established benefits in terms of decreased mortality. Despite the use of statin therapy, 10%-20% of high- and very-high-risk patients do not reach their LDL-C targets. There is an urgent need for improved strategies to manage dyslipidemia, especially among patients with homozygous familial hypercholesterolemia, but also in patients with established cardiovascular disease who fail to achieve LDL goals despite combined statin, ezetimibe, and PCSK9 inhibitor (PCSK9i) therapy. Inclisiran is a disruptive, first-in-class small interfering RNA (siRNA)-based therapeutic developed for the treatment of hypercholesterolemia that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis, thereby upregulating the number of LDL receptors on the hepatocytes, thus lowering the plasma LDL-C concentration. Inclisiran decreases the LDL-C levels by over 50% with one dose every 6 months, making it a simple and well-tolerated treatment strategy. In this review, we summarize the general information regarding (i) the role of LDL-C in atherosclerotic cardiovascular disease, (ii) data regarding the role of PCSK9 in cholesterol metabolism, (iii) pleiotropic effects of PCSK9, and (iv) the effects of PCSK9 silencing. In addition, we focus on inclisiran, in terms of its (i) mechanism of action, (ii) biological efficacy and safety, (iii) results from the ORION trials, (iv) benefits of its combination with statins, and (v) its potential future role in atherosclerotic cardiovascular disease.

Citing Articles

Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection.

Stuben B, Hoyer D, Radunz S, Saner F, Schmidt H, Baba H Case Reports Hepatol. 2024; 2024:5556907.

PMID: 38249623 PMC: 10796182. DOI: 10.1155/2024/5556907.

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9.

Wolowiec L, Osiak J, Wolowiec A, Wijata A, Grzesk E, Kozakiewicz M Pharmaceutics. 2023; 15(2).

PMID: 36839644 PMC: 9965021. DOI: 10.3390/pharmaceutics15020323.

Inclisiran: a novel drug for the treatment of dyslipidemia.

Nadeem A, Tariq R, Basaria A Ann Med Surg (Lond). 2023; 85(1):59-60.

PMID: 36742122 PMC: 9893436. DOI: 10.1097/MS9.0000000000000089.

Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis.

Zubieliene K, Valteryte G, Jonaitiene N, Zaliaduonyte D, Zabiela V Medicina (Kaunas). 2022; 58(11).

PMID: 36422206 PMC: 9692978. DOI: 10.3390/medicina58111665.

TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.

Filipiak K, Camafort Babkowski M, Cameli M, Carugo S, Ferri C, Irisov D Cardiol J. 2022; 29(5):730-738.

PMID: 36117294 PMC: 9550320. DOI: 10.5603/CJ.a2022.0087.

References

Liao F, Andalibi A, Lusis A, Fogelman A . Genetic control of the inflammatory response induced by oxidized lipids. Am J Cardiol. 1995; 75(6):65B-66B. DOI: 10.1016/0002-9149(95)80015-k. View

Hassan M . OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events. Glob Cardiol Sci Pract. 2015; 2015(2):20. PMC: 4625402. DOI: 10.5339/gcsp.2015.20. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Barquera S, Pedroza-Tobias A, Medina C, Hernandez-Barrera L, Bibbins-Domingo K, Lozano R . Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch Med Res. 2015; 46(5):328-38. DOI: 10.1016/j.arcmed.2015.06.006. View

Gallego-Colon E, Daum A, Yosefy C . Statins and PCSK9 inhibitors: A new lipid-lowering therapy. Eur J Pharmacol. 2020; 878:173114. DOI: 10.1016/j.ejphar.2020.173114. View

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

Seidah N . New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications. Curr Opin Lipidol. 2016; 27(3):274-81. DOI: 10.1097/MOL.0000000000000295. View

Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K . Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001; 21(6):955-60. DOI: 10.1161/01.atv.21.6.955. View

Ding Z, Liu S, Wang X, Deng X, Fan Y, Sun C . Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2014; 22(9):760-71. PMC: 4361218. DOI: 10.1089/ars.2014.6054. View

10.

Kam N, Perera K, Zomer E, Liew D, Ademi Z . Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. Pharmacoeconomics. 2020; 38(9):1007-1020. DOI: 10.1007/s40273-020-00948-w. View

11.

Hopkins P, Defesche J, Fouchier S, Bruckert E, Luc G, Cariou B . Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet. 2015; 8(6):823-31. PMC: 5098466. DOI: 10.1161/CIRCGENETICS.115.001129. View

12.

Giunzioni I, Tavori H, Covarrubias R, Major A, Ding L, Zhang Y . Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol. 2015; 238(1):52-62. PMC: 5346023. DOI: 10.1002/path.4630. View

13.

Khvorova A . Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017; 376(1):4-7. DOI: 10.1056/NEJMp1614154. View

14.

Lee C, Lee Y, Park S, Kim K, Park S, Youn J . Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 2013; 62(6):845-50. DOI: 10.1016/j.metabol.2013.01.005. View

15.

Humphries S, Whittall R, Hubbart C, Maplebeck S, Cooper J, Soutar A . Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006; 43(12):943-9. PMC: 2563208. DOI: 10.1136/jmg.2006.038356. View

16.

Zhao Z, Du S, Shen S, Luo P, Ding S, Wang G . Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Medicine (Baltimore). 2019; 98(6):e14400. PMC: 6380691. DOI: 10.1097/MD.0000000000014400. View

17.

Cheng J, Oemrawsingh R, Garcia-Garcia H, Boersma E, van Geuns R, Serruys P . PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016; 248:117-22. DOI: 10.1016/j.atherosclerosis.2016.03.010. View

18.

Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta J . LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 2003; 107(4):612-7. DOI: 10.1161/01.cir.0000047276.52039.fb. View

19.

Ruscica M, Corsini A, Ferri N, Banach M, Sirtori C . Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacol Res. 2020; 159:104916. PMC: 7238995. DOI: 10.1016/j.phrs.2020.104916. View

20.

Banach M, Stulc T, Dent R, Toth P . Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int J Cardiol. 2016; 225:184-196. DOI: 10.1016/j.ijcard.2016.09.075. View